Novo Holdings invest US$12m in AMR companies
Mutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund.
Fighting sepsis mortality
Critical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality.
Antabio SAS advances cystic fibrosis programme
Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients
Hydrogel fights wound infection and inflammation
Swedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds.
Merry Christmas and a Happy New Year
European Biotechnology Magazine will be back with breaking news and backgrounds on 2 January.
Best wishes
British diagnostics play OBD lands contract with US pharma
The technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate OBD’s epigenetic biomarker discovery and development platform causing a share price gain of 15%.
Truffle’s BioMedTech fund filled with 250m
Paris-based European venture capital company Truffle Capital closed its 250m BioMedTech fund celebrating its company building approach.
Biomarker identifies residual congestion in heart failure patients
Data from 1,200 heart failure patients demonstrate that high discharge levels of the biomarker bio-ADM® (bioactive Adrenomedullin) indicate residual congestion in heart failure patients.
Belgian start-up takes fight on neuropathies
The new company, named Augustine Therapeutics, is a Vlaams Instituut voor Biotechnologie (VIB) and Katholieke Universiteit (KU) Leuven spin-off. Funded with 4.2m from mainly local investors, Augustine’s first priority is finding new therapeutics for patients suffering from Charcot-Marie-Tooth disease, a hereditary motor and sensory neuropathy of the peripheral nervous system.
Second clinical failure of Transgene in 2019
French Transgene SA said it has terminated its lead programme TG4010 in combination with chemotherapy and checkpoint inhibition.